Surgical aortic valve (AV) replacement (AVR) is a gold standard for treatment of severe aortic stenosis (AS), however almost 1/3 of patients especially elderly, are not treated. The main reason is high periprocedural mortality caused by multiple risk factors in particular in patients older than 75 years in whom incidence of AS is almost 14%.
Although transcatheter AV implantation (TAVI) proved safe and efficient treatment of patients disqualified from AVR, substantial limitations such as high costs, complexity, bulky delivery systems and high risk of complications limit their widespread use.
The project aim is to develop the first Polish balloon-expandable, low-profile transcatheter AV using ultra low profile delivery system which would reduce the procedure-related adverse outcomes and costs, increase availability of TAVI and increase the competiveness of Polish companies.
The project is implemented in cooperation with leaders in cardiology, cardiac surgery, industry and science, having wide experience in medical technologies.